pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Orilissa
drug
save

elagolix sodium

Marketedupdated 3mo ago
by $ABBV AbbVie Inc.
Approved
community read0 votes

🐶 often sniffed alongside

top 7
  • tagApproval38 co-mentions · 12 sources
  • drugORILISSA33 co-mentions · 12 sources
  • tagSmall Molecule19 co-mentions · 12 sources
  • drugORIAHNN (COPACKAGED)10 co-mentions · 5 sources
  • drugelagolix sodium + estradiol + norethindrone + elagolix sodium5 co-mentions · 5 sources
  • drugESTRING5 co-mentions · 5 sources
  • drugnorethindrone5 co-mentions · 5 sources

Small molecule drug with a maximum clinical stage of Approval, with an approval for endometriosis.

all catalysts(7)

approval · 7
Jul 23, 2018
approval
$ABBV261.83-1.56%
8y ago
ORILISSA (ELAGOLIX SODIUM) — FDA approval
elagolix sodium
→
Aug 28, 2019
approval
$ABBV261.83-1.56%
7y ago
ORILISSA (ELAGOLIX SODIUM) — FDA approval
elagolix sodium
→
Feb 1, 2021
approval
$ABBV261.83-1.56%
6y ago
ORILISSA (ELAGOLIX SODIUM) — FDA approval
elagolix sodium
→
Feb 1, 2021
approval
$ABBV261.83-1.56%
6y ago
ORILISSA (ELAGOLIX SODIUM) — FDA approval
elagolix sodium
→
Feb 1, 2021
approval
$ABBV261.83-1.56%
6y ago
ORILISSA (ELAGOLIX SODIUM) — FDA approval
elagolix sodium
→
Jun 5, 2023
approval
$ABBV261.83-1.56%
3y ago
ORILISSA (ELAGOLIX SODIUM) — FDA approval
elagolix sodium
→
Dec 17, 2025
approval
$ABBV261.83-1.56%
8mo ago
ORILISSA (ELAGOLIX SODIUM) — FDA approval
elagolix sodium
→

Patent cliff

source: FDA Orange Book
first barrier falls
Jul 6, 2029
~2.9 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (13)

  • Aug 27, 2040method-of-use (U-3654)US 11690845
  • Aug 27, 2040method-of-use (U-3654)US 11690845
  • Jul 23, 2039compositionUS 11542239
  • Jul 23, 2039compositionUS 11542239
  • Aug 20, 2038formulationUS 12102637
  • Aug 20, 2038formulationUS 12102637
  • Apr 19, 2038method-of-use (U-3653)US 11690854
  • Sep 1, 2036method-of-use (U-2735)US 10537572
  • Sep 1, 2036method-of-use (U-2850)US 10682351
  • Mar 14, 2034method-of-use (U-3389)US 11344551
  • Mar 14, 2034method-of-use (U-3672)US 11707464
  • Jul 6, 2029compositionUS 74199832.9y
  • Jul 6, 2029compositionUS 74199832.9y

News(0)

no news has mentioned this drug yet

brand
Orilissa
generic
elagolix sodium
MOA
12.1 Mechanism of Action ORILISSA is a GnRH receptor antagonist that inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland. Administration of ORILISSA results in dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased blood concentrations of the ovarian sex hormones, estradiol and progesterone.
indication
Endometriosis
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 9m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?